Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine (Q43625547)

25 November 2017

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine (English)

1 reference

25 November 2017

0 references

1 reference

0 references

2

Gale Smith

1 reference

25 November 2017

Gregory M Glenn

1

1 reference

25 November 2017

Louis Fries

3

1 reference

25 November 2017

Rama Raghunandan

4

1 reference

25 November 2017

Hanxin Lu

5

1 reference

25 November 2017

Bin Zhou

6

1 reference

25 November 2017

D Nigel Thomas

7

1 reference

25 November 2017

Somia P Hickman

8

1 reference

25 November 2017

Eloi Kpamegan

9

1 reference

25 November 2017

Sarathi Boddapati

10

1 reference

25 November 2017

Pedro A Piedra

11

1 reference

25 November 2017

language of work or name

English

0 references

publication date

12 November 2012

1 reference

25 November 2017

1 reference

25 November 2017

31

1 reference

25 November 2017

524-532

1 reference

25 November 2017

3

1 reference

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Respiratory syncytial virus infection in elderly and high-risk adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

The burden of respiratory syncytial virus infection in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Role of serum neutralizing antibody in reinfection of respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Immunity to and frequency of reinfection with respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

New insights for development of a safe and protective RSV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Detection, pathogenesis, and therapy of respiratory syncytial virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Appropriate calibration curve fitting in ligand binding assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Prospects for defined epitope vaccines for respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Risk factors for severe respiratory syncytial virus infection in elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.11.009

1 reference

25 November 2017

1 reference